Business Context and Reporting Period
This Form 8-K Current Report was filed by Regis Corporation on June 20, 2025. The filing addresses significant changes in executive leadership, specifically the resignation of the Chief Executive Officer and the appointment of an interim successor.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on corporate governance and executive compensation arrangements.
Material Changes
- CEO Resignation: Matthew Doctor, President and CEO, notified the Board of his resignation, effective June 30, 2025.
- Interim Appointment: Jim Lain, Executive Vice President, Brand Operations, was appointed Interim President and CEO, effective July 1, 2025.
- Transition Period: Mr. Doctor will remain with the company as a part-time employee through August 31, 2025.
Guidance, Outlook, and Compensation Details
The Board has commenced a comprehensive search for a permanent CEO successor. The filing details specific compensation adjustments for the transition period:
- Jim Lain (Interim CEO):
- Base salary increased to $550,000.
- Target annual incentive increased to 100% of base salary.
- Eligible for a $100,000 interim service bonus.
- Matthew Doctor (Outgoing CEO):
- Will receive 50% of his current base salary during the transition term (July 1 – August 31, 2025).
- Remains eligible for payment under his fiscal 2025 annual incentive award.
Investor Verification Checklist
- Verify the terms of the Interim CEO Offer Letter Agreement (Exhibit 10.1) regarding Mr. Lain's bonus conditions.
- Review the Resignation and Transition Letter Agreement (Exhibit 10.2) for specific clauses regarding Mr. Doctor's part-time duties and incentive eligibility.
- Monitor the timeline for the permanent CEO search and any subsequent announcements regarding the appointment.
- Check the attached Press Release (Exhibit 99.1) for additional context on the strategic rationale for the leadership change.